Amundi Buys 52,166 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Amundi increased its holdings in Regeneron Pharmaceuticals by 3.4%, acquiring an additional 52,166 shares during the first quarter, bringing their total shares to approximately 1.6 million valued at $979.8 million.
• Recent earnings results showed Regeneron reporting EPS of $12.89 for the quarter, significantly surpassing the consensus estimate of $8.43, with a revenue increase to $3.68 billion.
• The company announced a quarterly dividend of $0.88 per share to be paid on September 3rd, representing an annualized yield of 0.6%.

Amundi boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,603,901 shares of the biopharmaceutical company's stock after acquiring an additional 52,166 shares during the period. Amundi owned 1.47% of Regeneron Pharmaceuticals worth $979,794,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC raised its position in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $343,764,000. Pacer Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after buying an additional 390,374 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Regeneron Pharmaceuticals by 171.0% in the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after acquiring an additional 303,785 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Regeneron Pharmaceuticals by 30.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after acquiring an additional 226,952 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on REGN. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Morgan Stanley reiterated an "overweight" rating and issued a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Citigroup reiterated a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Finally, Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded up $6.16 during mid-day trading on Friday, reaching $573.38. 959,753 shares of the stock traded hands, compared to its average volume of 949,804. The company has a market cap of $60.77 billion, a price-to-earnings ratio of 14.45, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The firm has a fifty day moving average price of $562.59 and a 200 day moving average price of $584.62. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,170.58.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company's revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company earned $11.56 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.